Betadex Sulfobutyl Ether Sodium (SEβCD), also known as sulfobutyl ether beta cyclodextrin sodium, is a Cyclodextrin derivative synthesized by β-Cyclodextrin and 1,4-BS(1,4-Butane Sultone) (CAS 182410-00-0). Due to the low solubility of β-Cyclodextrin, long-term storage may lead to drug precipitation; and it is nephrotoxic and lacks flexibility in the application of parenteral administration, so it was modified to Betadex Sulfobutyl Ether Sodium(SEβCD), effectively reduces the nephrotoxicity of β-Cyclodextrin and improves the solubility and blood compatibility, which promotes its excellent bioavailability and good tolerance in clinical use. It has also been approved for use in a number of pharmaceutical excipients by the United States Pharmacopoeia and the European Pharmacopoeia.
Betadex Sulfobutyl Ether Sodium (SEβCD) has excellent stability, permeability, solubility, low toxicity, and bioavailability. At present, it has been used in injection medicine, oral medicine, nasal medicine and eye medicine.
In addition, it can control the release time of the drug by placing drug molecules in the inner cavity, so that Sulfobutyl ether beta-cyclodextrin(SEβCD) is widely used in oral medicines, eye drops, nasal sprays, pulmonary drug delivery (PDD), intravenous injection, and topical skin medicine. Therefore, in recent years, sulfobutyl beta cyclodextrin sodium plays an important role in the field of medicine.
Xi'an Deli Biochemical Co., Ltd. is a high-tech enterprise specializing in research & development, production & sales of cyclodextrin and its derivatives. The company has focused on the research and production of cyclodextrin and its derivatives for 24 years. The company currently has products DELI Brand Hydroxypropyl Betadex, DELI Brand Betadex Sulfobutyl Ether Sodium. These products have been publicized in National Center for Drug Review (CDE) and registered in US Food and Drug Administration (FDA). The company can also customize products with special specifications according to customer needs.
